Skip to main content

Table 6 Sensitivity analysis of net budget impact of DUT + TAM FDC (€)

From: Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting

Year

1

2

3

4

Public sector

1,296,503

2,262,120

3,930,137

5,808,131

Prevalence of BPH

   

20%

864,336

1,553,230

2,752,483

4,195,474

40%

1,728,671

2,971,017

5,107,791

7,420,837

Only BPV > 50 cc

537,096

1,142,338

1,886,053

2,934,517

Probability that first and second TURPs are successful

88%

1,300,878

2,299,356

3,973,923

5,904,891

99%

1,305,243

2,336,509

4,017,601

6,001,441

Private sector

1,237,555

1,440,175

2,897,873

3,998,659

Prevalence of BPH

    

20%

825,037

993,147

2,031,237

2,892,582

40%

1,650,074

1,887,239

3,764,509

5,104,980

Only BPV > 50 cc

422,530

719,264

1,263,342

2,003,231

Probability that first and second TURPs are successful

   

88%

1,245,058

1,504,091

2,973,305

4,165,148

99%

1,252,516

1,567,598

3,048,198

4,330,599